Pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma
Cancer Research UK · CC BY-SA 4.0 · source
Name	Pancreatic ductal adenocarcinoma
Field	Oncology, Gastroenterology
Symptoms	Jaundice, abdominal pain, weight loss
Complications	Metastasis, biliary obstruction
Onset	Adult
Causes	Smoking, chronic pancreatitis, hereditary syndromes
Risks	Diabetes mellitus, obesity
Diagnosis	Imaging, biopsy, tumor markers
Treatment	Surgery, chemotherapy, radiation therapy
Prognosis	Poor

Pancreatic ductal adenocarcinoma is the most common malignant neoplasm of the pancreas and a leading cause of cancer mortality worldwide. It typically presents with nonspecific systemic and local manifestations, follows aggressive biological behavior, and is managed by multidisciplinary teams spanning surgical oncology, medical oncology, and radiation oncology. Major centers such as Mayo Clinic, Memorial Sloan Kettering Cancer Center, Johns Hopkins Hospital, MD Anderson Cancer Center, and institutions affiliated with National Institutes of Health conduct landmark trials that guide standards of care.

Signs and symptoms

Patients commonly report vague symptoms that include progressive weight loss, anorexia, abdominal or back pain, and new-onset diabetes mellitus; these findings often prompt evaluation at tertiary centers like Cleveland Clinic or Royal Marsden Hospital. Painless jaundice can occur with biliary obstruction, leading to referrals between hepatopancreatobiliary services at Karolinska University Hospital and Charité – Universitätsmedizin Berlin. Other manifestations include steatorrhea, pruritus, and cholangitis, which necessitate interventions by interventional radiology teams at hospitals such as Toronto General Hospital and Singapore General Hospital.

Causes and risk factors

Established risk factors include cigarette smoking, chronic alcohol use causing chronic pancreatitis, hereditary syndromes like Peutz–Jeghers syndrome, hereditary breast–ovarian cancer syndrome, and germline mutations in BRCA1 and BRCA2. Environmental exposures documented in occupational studies at agencies like World Health Organization and International Agency for Research on Cancer increase risk, while medical comorbidities such as long-standing type 2 diabetes mellitus and obesity noted by public health organizations including Centers for Disease Control and Prevention and Public Health England also contribute. Family history prompts genetic counseling involving centers like Dana-Farber Cancer Institute and guideline bodies such as National Comprehensive Cancer Network.

Pathophysiology and genetics

Tumorigenesis often follows progression from pancreatic intraepithelial neoplasia lesions via accumulation of driver mutations in genes including KRAS, TP53, CDKN2A, and SMAD4; seminal discoveries came from research groups at Cold Spring Harbor Laboratory and Broad Institute. Desmoplastic stroma, driven by activated pancreatic stellate cells and signaling pathways investigated at Max Planck Institute for Biology and Institut Pasteur, creates a hypovascular microenvironment that impairs drug delivery—a phenomenon studied in preclinical models at Dana-Farber Cancer Institute and University of California, San Francisco. Tumor immune evasion mechanisms have been compared to observations in studies from Karolinska Institutet and Imperial College London, informing translational trials led by collaborative groups like European Organisation for Research and Treatment of Cancer and American Society of Clinical Oncology.

Diagnosis

Diagnosis integrates cross-sectional imaging such as multiphase computed tomography scans performed at radiology departments in institutions like Massachusetts General Hospital and Guy's and St Thomas' NHS Foundation Trust, endoscopic ultrasound with fine-needle aspiration by teams at Ashton Biomedical Research Centre, and tumor marker assessment including CA 19-9 measured in clinical laboratories at hospitals like Royal Infirmary of Edinburgh. Multidisciplinary tumor boards following protocols from National Institute for Health and Care Excellence and European Society for Medical Oncology decide on biopsy, staging laparoscopy, or molecular profiling performed at genomic centers such as Peter MacCallum Cancer Centre and Wellcome Sanger Institute.

Staging and prognosis

Staging follows the TNM staging system endorsed by organizations such as Union for International Cancer Control and American Joint Committee on Cancer; resectability categories (resectable, borderline, locally advanced, metastatic) guide management in referral networks like European Reference Network. Prognosis is poor compared with many solid tumors—survival statistics reported by registries including Surveillance, Epidemiology, and End Results Program and Cancer Research UK show low five-year survival rates, with outcomes influenced by nodal status, margin status after surgery at centers like John Radcliffe Hospital, and molecular features identified by consortia such as International Cancer Genome Consortium.

Treatment

Curative-intent treatment is surgical resection (pancreaticoduodenectomy or distal pancreatectomy) performed at high-volume centers such as Hôpitaux Universitaires de Genève and Erasmus MC, often followed by adjuvant chemotherapy with regimens derived from trials at European Organisation for Research and Treatment of Cancer and National Cancer Institute; common systemic agents include combinations studied in trials at Vanderbilt University Medical Center and Seoul National University Hospital. For borderline or locally advanced disease, neoadjuvant chemotherapy and chemoradiation protocols developed by Johns Hopkins Hospital and Memorial Sloan Kettering Cancer Center increase resectability. Palliative measures include endoscopic stenting (performed by teams at Mayo Clinic), analgesia per guidelines of World Health Organization, and enrollment in clinical trials coordinated by groups such as Alliance for Clinical Trials in Oncology and NCI-CONNECT.

Epidemiology and prevention

Incidence and mortality trends from agencies like World Health Organization, Centers for Disease Control and Prevention, and International Agency for Research on Cancer show rising burden in aging populations in countries including United States, United Kingdom, Germany, Japan, and China. Primary prevention emphasizes tobacco control policies promoted by World Health Organization and metabolic risk modification advocated by World Obesity Federation and American Heart Association. Screening of high-risk cohorts is recommended by specialty societies such as International Cancer of the Pancreas Screening Consortium and performed at specialized centers including Mayo Clinic and University of Pittsburgh Medical Center.

Category:Pancreatic cancer